MUC5AC and neoplasm: Previously, we showed that MUC5AC-IR800 could brightly and specifically label the primary tumor and abdominal wall metastases with an average tumor-to-pancreas ratio of 2.183 (±0.619) in a patient-derived orthotopic xenograft model of pancreatic cancer (AA1305) [31].